EP 0926156 B1 20050921 - Vector comprising Mycobacterium tuberculosis 38 kDa antigen for neoplasm treatment
Title (en)
Vector comprising Mycobacterium tuberculosis 38 kDa antigen for neoplasm treatment
Title (de)
Vektor enthaltend Mycobacterium Tuberculosis 38 kDa Antigen zur Behandlung von Neoplasmen
Title (fr)
Vecteur comportant l'antigène de 38 kDa de Mycobacterium tuberculosis pour le traitement des néoplasmas
Publication
Application
Priority
- EP 98124375 A 19981222
- EP 97122698 A 19971222
Abstract (en)
[origin: EP0926156A2] The Mycobacterium tuberculosis Ag38 gene, which encodes a highly immunogenic protein, was cloned into a retroviral vector in-frame with the leader and the transmembrane portion of the nerve growth factor receptor, and transduced into murine melanoma cell line B16-B78. Significant protection was observed in mice immunized with the transduced melanoma cells and subcutaneously challenged with parental melanoma cells since only 20% of mice developed tumors. Necroscopy of mice immunized with the transduced melanoma cells revealed dramatic inhibition of experimental metastases induced by intravenous (i.v.) inoculation of parental melanoma cells. Moreover vaccination with transduced cells significantly prolonged survival of mice challenged i.v. with parental melanoma cells. These data indicate that the presence of the mycobacterial 38-kDa protein greatly enhances immunological recognition of structures expressed by the parental melanoma cells. Comparison of Th1 and Th2 responses in mice immunized with parental melanoma cells versus mice receiving the transduced cells revealed a clear predominance of Th1 responses when the Ag38 protein was endogenously expressed. This novel transduction approach based on the 38kDa antigen may represent a promising immunotherapeutic strategy for the treatment of cancer patients. In addition, as vaccine the transduced cells may be used for inducing immunity to cancer. <IMAGE>
IPC 1-7
IPC 8 full level
A61K 39/04 (2006.01); C07K 14/35 (2006.01); C12N 15/86 (2006.01); A61K 48/00 (2006.01)
CPC (source: EP US)
A61K 39/04 (2013.01 - EP); C07K 14/35 (2013.01 - EP); A61K 48/00 (2013.01 - EP); A61K 2039/5156 (2013.01 - EP US); A61K 2039/53 (2013.01 - EP); C07K 2319/02 (2013.01 - EP); C07K 2319/03 (2013.01 - EP); C12N 2799/022 (2013.01 - EP); C12N 2799/027 (2013.01 - EP)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE
DOCDB simple family (publication)
EP 0926156 A2 19990630; EP 0926156 A3 20001206; EP 0926156 B1 20050921; AT E305012 T1 20051015; DE 69830135 D1 20050616; DE 69830135 T2 20060706
DOCDB simple family (application)
EP 98124375 A 19981222; AT 98124375 T 19981222; DE 69830135 T 19981222